Saxenda vs Trulicity

Saxenda (liraglutide 3 mg) and Trulicity (dulaglutide) are often grouped together because both are GLP-1 receptor agonists, but the FDA approved them for different conditions and they are not interchangeable. Saxenda's label is chronic weight management; Trulicity's label is type 2 diabetes plus cardiovascular risk reduction. Class similarity does not make them substitutes — the patient's primary diagnosis, the FDA indication, and the insurance pathway determine which drug a prescriber reaches for. The two are also dosed differently: Saxenda is a daily injection, Trulicity is once weekly.

FDA-Approved Indications Are Different

Saxenda is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity such as hypertension or dyslipidemia. The label also covers adolescents aged 12 to 17 with body weight over 60 kg and a BMI corresponding to adult obesity (added in December 2020). Trulicity is indicated as an adjunct to diet and exercise in adults with type 2 diabetes mellitus, and for reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Using Saxenda to target A1C, or Trulicity to target weight alone, falls outside each label — insurance coverage tracks the label, and prescribers treat within it.

Molecule, Dose, and Administration

Saxenda is liraglutide dosed up to 3.0 mg daily by subcutaneous injection via multi-dose pen, with a 0.6 mg starter and weekly 0.6 mg steps through 1.2, 1.8, and 2.4 mg to the 3.0 mg maintenance dose. Trulicity is dulaglutide dosed at 0.75 to 4.5 mg once weekly by subcutaneous auto-injector, typically starting at 0.75 mg for four weeks before moving to 1.5 mg and, if needed, 3 mg and 4.5 mg. The molecules are structurally different: dulaglutide is a GLP-1 analogue fused to a modified IgG4-Fc antibody fragment, while liraglutide is a lipid-modified peptide with a much shorter half-life.

Efficacy Data in Their Respective Labeled Conditions

Saxenda 3 mg in the SCALE Obesity and Prediabetes trial (Pi-Sunyer 2015) produced about 8% mean weight loss (roughly 8.4 kg) at 56 weeks, with approximately 63% of patients achieving at least 5% loss. Trulicity 1.5 mg weekly in the AWARD program reduced A1C by about 1.1 to 1.5 percentage points over 26 weeks, and the REWIND cardiovascular outcomes trial showed a 12% reduction in major adverse cardiovascular events over a median 5.4 years in 9,901 patients with type 2 diabetes. Weight change on Trulicity runs approximately 2 to 3 kg as a secondary observation in its diabetes trials. These studies measured different primary endpoints in different populations, so head-to-head weight-loss numbers do not translate cleanly between them.

Coverage and Access

Saxenda coverage is restrictive because many commercial plans exclude weight-management medications, and Medicare Part D does not cover Saxenda for obesity under the Medicare Modernization Act. Trulicity coverage is broad for type 2 diabetes across commercial plans and Medicare Part D with prior authorization. For patients who meet the criteria for both a weight-management agent and a diabetes agent, a dual-indication molecule under its matching label — for example, semaglutide as Ozempic for diabetes and Wegovy for obesity, or tirzepatide as Mounjaro for diabetes and Zepbound for obesity — is often the cleaner path. The choice always starts with the primary condition and the FDA label that supports treatment for it.